Compound heterozygosity for two novel mutations of the SEC23B gene in congenital dyserythropoietic anemia type II

Int J Hematol. 2021 Sep;114(3):390-394. doi: 10.1007/s12185-021-03155-1. Epub 2021 Apr 29.

Abstract

Congenital dyserythropoietic anemia type II (CDA II), a rare genetic disorder, results from SEC23B gene mutations according to previous studies. Here, we present a case of CDA II involving two novel pathogenic mutations of SEC23B that have not previously been reported. The patient suffered from jaundice, tea-colored urine, and weakness. Laboratory data indicated moderately decreased hemoglobin, iron overload, and abnormal erythroblast morphology. Therefore, a diagnosis of CDA II was considered. Peripheral blood samples were used to perform whole exome sequencing, and the results showed compound heterozygosity of the SEC23B gene with the following mutations: c.1162T>A (p.F388I) and c.1603delC (p.R535del). The mutant proteins were predicted to be deleterious and resulted in decreased structural stability. PyMOL software was used to analyze the structural change caused by the p.F388I missense mutation, and the results indicated a deficiency in π-π interactions. In conclusion, our report extends the mutation spectrum of SEC23B in the diagnosis of CDA II.

Keywords: CDA II; Exome sequencing; Mutation; SEC23B.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Alleles
  • Anemia, Dyserythropoietic, Congenital / diagnosis*
  • Anemia, Dyserythropoietic, Congenital / genetics*
  • Biopsy
  • Bone Marrow / metabolism
  • Exome Sequencing
  • Genetic Association Studies* / methods
  • Genetic Predisposition to Disease*
  • Heterozygote*
  • Humans
  • Male
  • Mutation*
  • Pedigree
  • Symptom Assessment
  • Tomography, X-Ray Computed
  • Vesicular Transport Proteins / chemistry
  • Vesicular Transport Proteins / genetics*

Substances

  • SEC23B protein, human
  • Vesicular Transport Proteins